Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Bloodstream Infection
Interventions: Accelerate PhenoTest™ BC kit, Standard of Care; Diagnostic Test
Lead sponsor: Accelerate Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity
Interventions: Sitagliptin Phosphate; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Fetal Atrial Flutter Without Hydrops, Fetal Supraventricular Tachycardia Without Hydrops, Fetal Supraventricular Tachycardia With Hydrops
Interventions: Digoxin (monotherapy), Sotalol (monotherapy), Flecainide (monotherapy), Digoxin (dual therapy), Sotalol (dual therapy), Flecainide (dual therapy); Drug
Lead sponsor: Edgar Jaeggi; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Ischemic Stroke
Interventions: Enhanced Stroke Education, Usual Stroke Education; Behavioral
Lead sponsor: Washington Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Heart Diseases, Left Ventricular Dysfunction
Interventions: Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glipizide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: PF-06650833; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: BIIB091; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Hyperglycemia, Diabetes
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 3,184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Cilostazol 100 mg tablets, Pletal® 100 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Diabetes, Surgery
Interventions: Lantus, Insulin; Drug · Other
Lead sponsor: Tamra Dukatz; Other
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Royal Oak, Michigan • Troy, Michigan

Conditions: Cystic Fibrosis
Interventions: Acute Antioxidant, Chronic Antioxidant, Placebo; Dietary Supplement · Other
Lead sponsor: Augusta University; Other
Eligibility: 7 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Obesity, Childhood
Interventions: protein-sparing modified fast diet; Other
Lead sponsor: Ihuoma Eneli; Other
Eligibility: 11 Years to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Stroke
Interventions: BE-FAST, FAST; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Green Bay, Wisconsin

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Amisodin, Placebo; Drug · Other
Lead sponsor: PRG Science & Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain
Interventions: Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Raltegravir, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Surgical Incision, Nose Deformity
Interventions: Closure with Permanent Suture, Closure with Resorbable Suture; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Overweight, Obese, Spinal Cord Injury
Interventions: Lifestyle Intervention, Exercise Control; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions: Collection of genetic material; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 1,152 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Philips FAST SpO2 with Masimo Pulse Oximetry Sensors; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hypoglycemia, Type1diabetes
Interventions: Fasting, Feeding; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

Incretin Effect in People With Impaired Fasting Glucose

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)

REcurrent Stroke Prevention Through Personalized Education by Clinical Trainers (RESPPECT Trial)

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Effect of Exenatide on Liver and Heart Fat and Inflammation

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

Diabetes in the Perioperative Period

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

Perioperative Insulin Glargine Dosing Study

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

A Protein-sparing Modified Fast for Children and Adolescents With Severe Obesity (PSMF)

BE FAST vs. FAST: A Study in the General Public.

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Rhinoplasty Scar Comparison

Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes